Ipsen: presents NAPOLI 3 phase III trial
The investigational Onivyde® treatment (irinotecan liposome injection) in the NALIRIFOX treatment regimen demonstrated statistically significant improvements in overall survival and progression-free survival compared to nab-paclitaxel plus gemcitabine with a manageable safety profile.
' These results represent a potential breakthrough in an aggressive and difficult-to-treat cancer' says the group.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction